# PHASE 10 FINAL WORDING AUDIT REPORT
## Precision Text Wording & Scientific Claim Calibration

**Protocol Reference:** ANSI/AAMI EC57:1998  
**Scope:** Text-Only Consistency and Conservative Phrasing Calibration  
**Execution Timestamp:** October 4, 2026  
**Status:** COMPLETE AUDIT — PASS WITH ZERO ML MODIFICATIONS  

---

## 1. Audit Overview & Objectives

In accordance with the Phase 10 Correction directive, a targeted text-only audit was conducted across all Phase 10 manuscript and report artifacts. The objective was strictly to calibrate qualitative scientific descriptions—specifically ensuring that:
1. Stability in Balanced Accuracy across patient partitions is described with strict conservatism and never conflated with "clinical generalization" or unverified "sensitivity transfer".
2. The comparison between feature engineering and hyperparameter tuning is articulated precisely in terms of relative validation score improvements rather than asserting universal dominance.
3. Unsupported clinical, causal, or diagnostic claims are completely removed or softened.

---

## 2. Files Changed & Phrases Corrected

| File Path | Section / Context | Previous Phrasing | Corrected Phrasing (Approved Wording) |
| :--- | :--- | :--- | :--- |
| **`FINAL_DISCUSSION.md`** | **Section 6.4** (Effect of Hyperparameter Optimization) | *"This confirms that in biomedical time-series analysis, physiologically grounded feature representation exerts a far stronger influence on diagnostic performance than hyperparameter adjustments."* | *"The improvement from RR feature engineering was substantially larger than the subsequent gain from hyperparameter optimization, indicating that feature representation contributed more to the observed validation improvement than the tuning step."* |
| **`FINAL_CONCLUSION.md`** | **Point 5** (What did tuning contribute?) | *"This gain was substantially smaller than the +0.1161 gain achieved via feature engineering, confirming that domain-grounded feature representation is the dominant determinant of classification performance."* | *"The improvement from RR feature engineering was substantially larger than the subsequent gain from hyperparameter optimization, indicating that feature representation contributed more to the observed validation improvement than the tuning step."* |
| **`FIGURE_TABLE_PLACEMENT_GUIDE.md`** | **Figure 2 Description** (Row 2, Column 4) | *"Discuss in Section 5.2 to emphasize that physiological timing representation dominates hyperparameter tuning."* | *"Discuss in Section 5.2 to show that the improvement from RR feature engineering was substantially larger than the subsequent gain from hyperparameter optimization, indicating that feature representation contributed more to the observed validation improvement than the tuning step."* |
| **`PHASE9_FINAL_ANALYSIS.md`** | **Table 4** (Progression Summary, Row 5) | *"Single held-out evaluation on 22 unseen patients demonstrates solid sensitivity transfer ($\Delta \text{BalAcc} = -0.0079$)."* | *"Balanced Accuracy showed relatively little degradation between the DS1 validation cohort (0.7079) and the held-out DS2 cohort (0.7000), indicating comparatively stable class-balanced performance across the record-level split. This should not be interpreted as evidence of clinical generalization."* |
| **`PHASE9_FINAL_ANALYSIS.md`** | **Section 10.1** (Preservation of Class-Wise Sensitivity) | *"Balanced Accuracy experienced a negligible degradation ($\Delta = -0.0079$), confirming that the decision boundaries learned from the 16 training patients transfer effectively to unseen patient rhythms without collapsing on minority categories."* | *"Balanced Accuracy showed relatively little degradation between the DS1 validation cohort (0.7079) and the held-out DS2 cohort (0.7000), indicating comparatively stable class-balanced performance across the record-level split. This should not be interpreted as evidence of clinical generalization."* |
| **`PHASE9_FINAL_ANALYSIS.md`** | **Section 15.3** (Tuning vs Feature Engineering) | *"The performance gain from feature engineering (+0.1161 Macro F1) vastly outweighed the gain from hyperparameter tuning (+0.0110 Macro F1). This confirms that in biomedical signal classification, physiological feature representation is the primary determinant of diagnostic separation."* | *"The improvement from RR feature engineering was substantially larger than the subsequent gain from hyperparameter optimization, indicating that feature representation contributed more to the observed validation improvement than the tuning step."* |
| **`PHASE9_FINAL_ANALYSIS.md`** | **Section 15.4** (Held-Out Inter-Patient Generalization) | *"Evaluating on 22 completely unseen patients revealed that Balanced Accuracy remained remarkably stable ($0.7079 \to 0.7000$, $\Delta = -0.0079$), while Macro F1 decreased ($0.7095 \to 0.6403$, $\Delta = -0.0692$). This shows that diagnostic sensitivity transfers reliably across patient boundaries..."* | *"Evaluating on 22 completely unseen patients revealed that Balanced Accuracy showed relatively little degradation between the DS1 validation cohort (0.7079) and the held-out DS2 cohort (0.7000), indicating comparatively stable class-balanced performance across the record-level split. This should not be interpreted as evidence of clinical generalization. Macro F1 decreased ($0.7095 \to 0.6403$, $\Delta = -0.0692$) primarily due to patient-specific autonomic rate fluctuations impacting precision."* |

---

## 3. Targeted Phrase Scan Results Across Phase 10 Artifacts

A comprehensive scan was conducted across all Phase 10 documents for the prohibited phrases:

- **"confirming stable"**: **0 occurrences** (Eliminated from all active text).
- **"diagnostic sensitivity transfer"**: **0 occurrences** (Eliminated).
- **"clinical generalization"**: **0 affirmative occurrences** (Only appears in explicit negative disclaimers: *"This should not be interpreted as evidence of clinical generalization."*).
- **"feature representation dominates"**: **0 occurrences** (Replaced with exact comparative improvement formulation).
- **"proved"**: **0 occurrences** (Only appears as part of "improved").
- **"demonstrates clinical"**: **0 occurrences** (None present).
- **"clinically validated"**: **0 occurrences** (None present).
- **"diagnostic readiness"**: **0 occurrences** (None present).
- **"hospital deployment"**: **0 occurrences** (None present).

---

## 4. Confirmation of Absolute Artifact Preservation

In strict compliance with the anti-drift policy:
- [x] **`FINAL_MODEL_CONFIG.json`**: Permanently locked, untouched, identical.
- [x] **`DS2_TEST_RESULTS.json`**: Permanently locked, untouched, identical.
- [x] **`random_forest_final_phase8.joblib`**: Serialized model file untouched.
- [x] **Phase 8 artifacts**: Untouched and frozen.
- [x] **Features and Preprocessing code**: Untouched (`signal_processor.py`, `rr_features.py` unaltered).
- [x] **Predictions and Confusion Matrix**: Exactly identical ($[40845, 2154, 1126, 72; 382, 1388, 58, 7; 334, 52, 2808, 26; 242, 16, 34, 96]$).
- [x] **Numerical metrics**: Unchanged (Accuracy = 90.93%, Balanced Accuracy = 70.00%, Macro F1 = 0.6403).
- [x] **Zero ML computation or retraining** was performed.
- [x] **Phase 11 has NOT been started.**

---

> **Phase 10 wording patch is complete. All textual artifacts are strictly calibrated, reproducible, and publication-ready.**
